Please check your internet connection and try again.
# Xone (ceftriaxone)
## Overview
Ceftriaxone is a third-generation, long-acting cephalosporin antibiotic. It provides broad-spectrum coverage against many Gram-positive and Gram-negative organisms, including *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria* species. It has a long half-life allowing for once-daily dosing.
## Primary Indications
* Community-acquired pneumonia
* Meningitis
* Complicated intra-abdominal infections
* Gonorrhea (uncomplicated)
* Pyelonephritis and complicated UTIs
* Bacterial septicemia
* Surgical prophylaxis
## Adult Dosing
* **Standard infections:** 1–2 g IV/IM every 24 hours.
* **Meningitis:** 2 g IV every 12 hours (may start with a loading dose of 2 g).
* **Uncomplicated Gonorrhea:** 500 mg IM as a single dose (increase to 1 g if body weight ≥150 kg).
* **Maximum dose:** Typically 4 g/day for severe infections.
## Pediatric Dosing
* **General infections:** 50–75 mg/kg IV/IM once daily.
* **Meningitis:** 80–100 mg/kg/day IV divided every 12–24 hours (max 4 g/day).
* **Neonates (≥ 28 days corrected age):** 50 mg/kg/day once daily.
* **Note:** Dosing varies significantly based on infection severity and age; consult local pediatric formulary or pediatric infectious disease guidelines.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment is required for patients with renal impairment, provided liver function is normal.
* **Hepatic Impairment:** In cases of severe concurrent hepatic and renal impairment, do not exceed 2 g/day without monitoring serum concentrations.
* **Dialysis:** Supplemental dosing is generally not required.
## Contraindications
* **Hypersensitivity:** Known severe hypersensitivity to ceftriaxone or any cephalosporin.
* **Neonates (≤ 28 days):** Concurrent use with calcium-containing IV solutions (including Ringer’s lactate or TPN) due to the risk of ceftriaxone-calcium precipitate in the lungs and kidneys.
## Adverse Effects
* **Common:** Injection site pain (IM), diarrhea, rash, eosinophilia.
* **Serious:** Biliary sludge/pseudolithiasis (secondary to biliary calcium-ceftriaxone precipitation), *Clostridioides difficile*-associated diarrhea, hemolytic anemia, and anaphylaxis.
## Key Drug Interactions
* **Calcium-containing products:** Absolute contraindication in neonates. Avoid in older patients via the same IV line (Y-site incompatibility).
* **Oral Anticoagulants:** May enhance the effect of Vitamin K antagonists (e.g., warfarin); monitor INR.
## Monitoring
* Monitor for signs of hypersensitivity (anaphylaxis).
* Monitor for diarrhea and symptoms of *C. difficile*.
* Assess for biliary symptoms (RUQ pain) in patients receiving prolonged therapy.
* Monitor CBC and LFTs in long-term therapy (> 14 days).
## Clinical Pearls
* **IM Administration:** When administering IM, reconstitute with 1% lidocaine (if no lidocaine allergy) to reduce injection site pain.
* **Spectrum:** It lacks activity against *Enterococcus* species, *Listeria monocytogenes*, and MRSA.
* **Dosing protocol:** Always defer to institutional antibiograms and local antimicrobial stewardship guidelines for specific site-of-infection dosing.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, dosing guidelines, and institutional protocols before administering medication.*
